Jul. 2 at 1:55 PM
The autoimmune cell therapy wave mostly runs through autologous CAR-T, which is expensive and inpatient. #ArtivaBio (Nasdaq:
$ARTV ) is trying an off-the-shelf route: AlloNK, a donor-derived NK cell therapy paired with rituximab to reset B cells in refractory rheumatoid arthritis. June's EULAR data read well and the FDA granted RMAT designation. The counts are still thin, so a funded Phase 3 is the real test.
https://prismmarketview.com/artivas-off-the-shelf-answer-to-autoimmune-car-t/
